Illumina Inc., ILMN is in the exchange NASDAQ and its industry is Biotechnology in the sector of Healthcare. Based in USA, Illumina Inc., ILMN has a market cap of 24305.26. Since its IPO date on the 7/28/2000, Illumina Inc., ILMN performance year to date is -14.01%. Today Illumina Inc., ILMN has gained 0.97%, with a current price of 166.65.
Ownership of the company is 1.20% for insider ownership while institutional ownership is 97.00%. The management of the company have seen the company have a payout ratio of 0.00%. Return of assets are at 11.40%, with return on investment at 16.60%.
In terms of debt levels and profit levels, Illumina Inc., ILMN is seeing a long-term debt/equity of 0.48. While Total debt/equity is 0.48. With a profit margin of 18.70%, this is combined with a gross margin of 70.00%, and operating margin of 24.60%. Illumina Inc. ability to meet debt levels, with a current ratio of 3.7, while the quick ratio is 3.1.
For the last year Illumina Inc., ILMN has seen a EPS growth of 30.50%. A performance for the year of -22.99%. The 52-week high is -24.03%, and the 52-week low is 31.12%. The average volume for Illumina Inc., ILMN is 239151.
With a target price of 154.88, can Illumina Inc., ILMN reach this target? Looking at the value indicators of Illumina Inc., ILMN. Illumina Inc. has a P/E of 56.74 and a forward P/E of 40.58. Perhaps the more useful indicator than P/E, is PEG which has a value of 3.55. Illumina Inc. also has a P/S and a P/B of 10.5 and 11.32 respectively. For P/cash, Illumina Inc. has a value of 17.05, while it is *TBA for P/free cash flow.
At the current price of 166.65, Illumina Inc. has a dividend yield of *TBA. We see a return on equity of 21.90%.
Looking more long-term Illumina Inc., is projected to get an EPS growth for the next five years of 15.97%. In the short-term an EPS growth of 15.87% in the next year is forecasted. This is after a EPS growth of 30.50% for this year and for the last five years a 28.90% growth has been seen.